Altheos to invest in development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has finished a $20 million Series A financing led by Bay City Capital. The permit also includes a series of highly active compounds specifically for topical treatment for glaucoma description . ‘No therapeutics based upon new mechanisms-of-action have been accepted for glaucoma in 15 years.D., CEO of Altheos.’ Related StoriesIRIDEX launches novel intra-ocular pressure monitoring deviceQuethera receives seed expense funding to build up gene therapy for glaucomaScientists elucidate genetic conversation that may prove important to advancement, progression of glaucomaAs area of the funding, Lester Kaplan, Ph.D., an associate of Bay City Capital’s scientific advisory panel and former President, Development and Research, and Panel Member at Allergan, Inc.

In fact, it really is a leading cause of follow-up surgeries. The Innovative Birmingham Hip Resurfacing Program is manufactured by Smith & Nephew Inc. Of Memphis.. Option to hip replacement There is a new option for patients experiencing hip pain who usually do not want to give up their active lifestyle. NewYork-Presbyterian/Columbia University INFIRMARY is one of the first hospitals in the U.S. To offer a new choice for total hip replacement – hip resurfacing. The technique enables the orthopedic surgeon to shave and cap several centimeters of bone within the hip joint, helping to protect bone and joint stability for active or youthful patients. The Innovative Birmingham Hip Resurfacing Program preserves even more of the patient’s natural bone structures and stability, covering the joint’s surfaces with an all-metal implant that more closely resembles a tooth cap when compared to a hip implant.